May. 13 at 10:53 AM
$SRXH It has been ages it seems but bears keep mixing up exchanges and compliance standards. The deficiency disclosed was tied to NYSE American stockholders’ equity requirements , not a Nasdaq-style
$1 bid rule. The subsequent Series B financing materially strengthened the balance sheet and appears to have resolved the stockholders’ equity deficiency, with 👉insiders participating and warrants priced at
$0.3182 🔥
More importantly, the company proceeded through the S-4/S-4A process and filed the Notice of Effectiveness. Companies generally do not advance this far through a major merger-registration process while facing unresolved listing concerns with the exchange. NYSE American also does not always issue a separate public “cure confirmed” announcement once compliance metrics are satisfied.
It’s time for 🤜⭕️⭕️⭕️⭕️⭕️⭕️⭕️⭕️⭕️🚀